Olmesartan Medoxomilo + Hidroclorotiazida Pharmakern (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan Medoxomilo + Hidroclorotiazida Pharmakern is used in cardiovascular therapy to lower blood pressure and reduce cardiovascular risk.

• Hypertension: Helps lower systolic and diastolic blood pressure in patients with primary hypertension.
• Heart failure: Assists in managing fluid overload and blood pressure in certain heart failure patients.
• Diabetic nephropathy: Provides renal protection by controlling hypertension in patients with type 2 diabetes.

• Olmesartan medoxil blocks the binding of angiotensin II to the AT‑1 receptor on vascular smooth‑muscle cells, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting diuresis and further lowering blood pressure. The combined actions produce additive antihypertensive effects.

Adverse reactions may occur with any antihypertensive regimen and should be monitored during therapy.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue
• Increased urination
• Electrolyte disturbances (e.g., low potassium)

Serious or Rare Side Effects

• Angio‑edema
• Severe hypotension
• Acute kidney injury
• Hyperkalemia
• Liver function abnormalities
• Severe skin reactions such as Stevens‑Johnson syndrome

Before prescribing Olmesartan Medoxomilo + Hidroclorotiazida, clinicians should evaluate patient history and monitor relevant parameters.

• Renal function: Assess baseline creatinine and eGFR before initiating therapy.
• Electrolytes: Monitor serum potassium and sodium levels regularly.
• Pregnancy: Contraindicated in the second and third trimesters due to fetal toxicity.
• Concomitant NSAIDs: Use with caution as they may reduce antihypertensive efficacy and affect renal function.
• Hypersensitivity: Discontinue if signs of angio‑edema or severe rash develop.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Olmesartan Medoxomilo + Hidroclorotiazida may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Alkaline‑alkaline ​  :  Co‑co   ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​
• Potassium‑sparing diuretics: May cause hyper‑kalaemia.
• Lithium: May increase lithium levels and toxicity risk.
• ACE inhibitors or other ARBs: Additive hypotensive effect; monitor blood pressure.

Moderate Interactions (Monitor Closely)

• NSAIDs: May blunt antihypertensive response and affect renal function.
• Antidiabetic drugs: May require dose adjustment due to enhanced glucose‑lowering effect.
• CYP‑3A4 inhibitors: May increase olmesartan exposure.
• Loop diuretics: Combined diuretic effect may lead to excessive volume depletion.
• Antacids containing magnesium or aluminium: May reduce absorption of olmeset‑